Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML-Reference-Cited by-同舟云学术

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Published:2013-10-17 Issue:16 Volume:122 Page:2877-2887
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chaturvedi Anuhar¹,Araujo Cruz Michelle Maria¹,Jyotsana Nidhi¹,Sharma Amit¹,Yun Haiyang¹,Görlich Kerstin¹,Wichmann Martin¹,Schwarzer Adrian²,Preller Matthias³,Thol Felicitas¹,Meyer Johann²,Haemmerle Reinhard²,Struys Eduard A.⁴,Jansen Erwin E.⁴,Modlich Ute²,Li Zhixiong²,Sly Laura M.⁵,Geffers Robert⁶,Lindner Robert⁷,Manstein Dietmar J.³,Lehmann Ulrich⁸,Krauter Jürgen¹,Ganser Arnold¹,Heuser Michael¹

Affiliation:

1. Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation,

2. Institute of Experimental Hematology, and

3. Institute for Biophysical Chemistry and Research Division for Structural Analysis, Hannover Medical School, Hannover, Germany;

4. Department of Clinical Chemistry, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands;

5. Child and Family Research Institute, University of British Columbia, Vancouver, BC, Canada;

6. Department of Cell Biology and Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany; and

7. Institute of Cell Biology, and

8. Institute of Pathology, Hannover Medical School, Hannover, Germany

Abstract

Key Points IDH1 promotes leukemogenesis in vivo in cooperation with HoxA9. Pharmacologic inhibition of mutant IDH1 efficiently inhibits AML cells of IDH1-mutated patients but not of normal CD34+ bone marrow cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/16/2877/1369856/2877.pdf

Reference46 articles.

1. An integrated genomic analysis of human glioblastoma multiforme.;Parsons;Science,2008

2. IDH1 and IDH2 mutations in gliomas.;Yan;N Engl J Med,2009

3. Recurring mutations found by sequencing an acute myeloid leukemia genome.;Mardis;N Engl J Med,2009

4. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.;Green;N Engl J Med,2010

5. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.;Thol;Haematologica,2010

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIWI-interacting RNAs (PiRNAs) as emerging biomarkers and therapeutic targets in biliary tract cancers: A comprehensive review;Heliyon;2024-07

2. Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors;Current Treatment Options in Oncology;2024-05-02

3. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05

4. IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation;Blood Cancer Discovery;2024-01-23

5. Approaches to autoimmune diseases using epigenetic therapy;Epigenetics in Human Disease;2024